Division of Mylan NV
Latest From Madaus GmbH
Rottapharm of Italy, which at the start of July was planning an initial public offering (IPO) by month-end, is to be acquired by Sweden's Meda for SEK21.2bn (€2.275bn).
The Italian pharmaceutical company Rottapharm Madaus is planning an initial public offering (IPO) of its shares later this month on the Italian Stock Exchange which will value the company at between €1.45bn–1.8bn.
Rottapharm has nothing to say about press rumours that its founding Rovati family is about to sell a 50% stake in the firm to private equity firms. A spokesperson for the Italian firm told Scrip that it had met funds in autumn 2011 "but nothing concrete had come of it" and the matter was closed.
The private Polish biotech company Selvita and Rottapharm Madaus of Italy have signed a drug discovery contract, under which Selvita will deliver a selection of compounds with therapeutic potential in an indicated area.
- OTC, Consumer
- Therapeutic Areas
- Madaus Pharma
- Madaus AG
- Western Europe
- Parent & Subsidiaries
- Mylan NV
- Senior Management
- Contact Info
Phone: (49) 22189980
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.